(CRGX) CARGO Therapeutics Common - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
CRGX: Cancer, Therapies, Chimeric, Antigen, CAR, T-cell
CARGO Therapeutics, Inc. (NASDAQ:CRGX) is a clinical-stage biotechnology company specializing in the development of innovative chimeric antigen receptor (CAR) T-cell therapies designed to treat cancer. The companys lead candidate, CRG-022, is an autologous CD22 CAR T-cell product targeting CD22, a tumor antigen expressed in B-cell malignancies. This approach aims to overcome resistance mechanisms that limit the efficacy of existing therapies. Additionally, CRG-023, a tri-specific CAR T product candidate, targets three B-cell antigen targets simultaneously, offering a novel strategy to enhance specificity and reduce relapse rates. Formerly known as Syncopation Life Sciences, Inc., the company rebranded as CARGO Therapeutics, Inc. in September 2022 to reflect its focus on advancing next-generation CAR T-cell therapies. Headquartered in San Mateo, California, CARGO Therapeutics, Inc. was incorporated in 2019 and is committed to addressing unmet needs in oncology. Web URL: https://cargo-tx.com
Based on the provided data, here is a 3-month forecast for CARGO Therapeutics, Inc. (NASDAQ:CRGX):
Technical Outlook: The stock is currently trading below its 20-day, 50-day, and 200-day moving averages, indicating bearish momentum. Average volume of 766,103 shares suggests moderate liquidity. The ATR of 0.94 indicates volatility, with potential price swings. Support levels may form near the current price of $3.68, but if broken, further downside is possible. A breakout above the 50-day SMA ($9.26) could signal a trend reversal.
Fundamental Outlook: With a market cap of $170.30M, CARGO Therapeutics, Inc. operates in a high-risk, high-reward environment typical of clinical-stage biotechnology companies. The P/B ratio of 0.42 suggests the stock may be undervalued relative to its book value. However, the negative return on equity (-38.45%) reflects ongoing losses, which are common in early-stage biotech firms. Investors should monitor clinical trial progress, particularly for CRG-022 and CRG-023, as well as any potential financing activities to support operations.
Additional Sources for CRGX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CRGX Stock Overview
| Market Cap in USD | 182m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2023-11-10 |
CRGX Stock Ratings
| Growth 5y | -46.1% |
| Fundamental | -61.1% |
| Dividend | 0.0% |
| Rel. Strength Industry | -83.8 |
| Analysts | 4.63/5 |
| Fair Price Momentum | 3.49 USD |
| Fair Price DCF | - |
CRGX Dividends
No Dividends PaidCRGX Growth Ratios
| Growth Correlation 3m | -73.3% |
| Growth Correlation 12m | -65.4% |
| Growth Correlation 5y | -52.4% |
| CAGR 5y | -61.29% |
| CAGR/Max DD 5y | -0.68 |
| Sharpe Ratio 12m | 0.19 |
| Alpha | -103.86 |
| Beta | 2.25 |
| Volatility | 87.09% |
| Current Volume | 302k |
| Average Volume 20d | 549.8k |
As of March 15, 2025, the stock is trading at USD 4.21 with a total of 302,039 shares traded.
Over the past week, the price has changed by +6.31%, over one month by +13.78%, over three months by -70.97% and over the past year by -85.01%.
No, based on ValueRay Fundamental Analyses, CARGO Therapeutics Common (NASDAQ:CRGX) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -61.06 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CRGX as of March 2025 is 3.49. This means that CRGX is currently overvalued and has a potential downside of -17.1%.
CARGO Therapeutics Common has received a consensus analysts rating of 4.63. Therefor, it is recommend to buy CRGX.
- Strong Buy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CRGX CARGO Therapeutics Common will be worth about 4 in March 2026. The stock is currently trading at 4.21. This means that the stock has a potential downside of -4.28%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 13.5 | 220.7% |
| Analysts Target Price | 31.7 | 653.2% |
| ValueRay Target Price | 4 | -4.3% |